My first exposure to pediatric rheumatology came during my adult rheumatology fellowship, when pediatric rotations were part of our curriculum. This experience brought home for me the many differences between childhood and adult rheumatic diseases and the important role pediatric rheumatologists play in patient outcomes. This role has long been appreciated by the ACR/ARP, where…
The new chair of the ACR’s Pediatric Rheumatology Committee, Ekemini A. Ogbu, MD, MSc, FAAP, describes how helping children and families navigate complex care brings a sense of fulfillment, purpose and “just joy.”
The FDA is reviewing supplemental biologics license applications for guselkumab to treat children with juvenile psoriatic arthritis and moderate to severe plaque psoriasis.
FDA has granted Descartes-08, an mRNA chimeric antigen receptor T cell therapy, a rare pediatric disease designation for the treatment of juvenile dermatomyositis.
WASHINGTON, D.C.—It is no small task to summarize an entire year’s worth of research accomplishments in any field of medicine, let alone one as complex as rheumatology. At ACR Convergence 2024, the Pediatric Year in Review not only provided a thoughtful summary, but also grouped advances along several different themes. Immune Health & More Jessica…
A session at ACR Convergence 2024 addressed several recent drug approvals in pediatric rheumatology and a safety update for IL-1/IL-6 inhibitors.
Doctors and patient advocates urged the rheumatology community to address the drastic inadequacies in care faced by marginalized people in a session held at ACR Convergence 2024.
At this ACR Convergence 2024 session, discussion centered on novel techniques that offer hope for developing personalized therapies for pediatric SLE.
Washington D.C.—At a Sunday, Nov. 17, Pediatrics Great Debate session of ACR Convergence, speakers argued whether patients with systemic juvenile idiopathic arthritis (sJIA) should continue their interleukin (IL) 1/IL-6 biologics if lung disease is suspected. Randy Q. Cron, MD, PhD, the director of the Division of Pediatric Rheumatology at the University of Alabama at Birmingham,…
On Nov. 16, the ACR Convergence 2024 session Toward Personalized Medicine in Pediatric Lupus will present important recent findings in the pathophysiology of pediatric lupus. Virginia Pascual, MD, is program director of an NIAID-funded Autoimmunity Center of Excellence and a NIAMS-funded Center for Lupus Research at Weill Cornell Medical College, New York. Her laboratory is…